McAdam LLC’s Tvardi Therapeutics TVRD Stock Holding History

McAdam LLC’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1	Closed	-$1K	–	645
2018 Q3	$1K	Hold	1	–	–	﹤0.01%	634
2018 Q2	$1K	Hold	1	–	–	﹤0.01%	603
2018 Q1	$0	Buy	+1	New	+$485	﹤0.01%	811

Other funds holding TVRD

RCP

Rho Capital Partners New York $20.4M AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

McAdam LLC's TVRD Position: Q4 2018 in Review

McAdam LLC sold out of Tvardi Therapeutics (TVRD) in Q4 2018, closing a stake of 1 share — an estimated $1K sold.

McAdam LLC first reported a position in TVRD in Q1 2018 and held it in 3 quarters. The position peaked at $1K in Q3 2018. 134 funds tracked by Wall St. Rank hold TVRD as of Q4 2018.

McAdam LLC reported no remaining Tvardi Therapeutics position as of Q4 2018 after selling out during the quarter.
McAdam LLC sold 1 Tvardi Therapeutics share in Q4 2018, an estimated $1K.
McAdam LLC first reported a position in Tvardi Therapeutics in Q1 2018 and held it in 3 quarters.
McAdam LLC's Tvardi Therapeutics position peaked at $1K in Q3 2018.
134 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2018.

Based on McAdam LLC's 13F filing for Q4 2018, filed 30 Jan 2019.